Share 'Solid Biosciences Granted U.S. and E.U. Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy'
Solid Biosciences and its subsidiary, Solid GT, announced today that the FDA and the European Commission have granted Orphan Drug designations for the company’s gene therapy candidate, SGT-001, for the treatment of people with Duchenne. Solid plans to initiate clinical studies for SGT-001 in 2017.
Read the announcement from Solid:
Solid Biosciences Granted U.S. and E.U. Orphan Drug Designati…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this